7 consecutive patients were enrolled from December 2002 to March 2006.
Procedures
In 6 patients, approximately 500 ml of autologous BM was aspirated from the ilium under general anesthesia, and collected into plastic bags containing heparin. In 1 patient, peripheral blood (PB)-MNCs were collected by cell apheresis. We sorted BM-or PB-MNCs using a blood-cell separator (Baxter, Deerfield, IL, USA) to 95% purity and concentrated them into a final volume of 30 ml within 2 h after aspiration. In 6 patients we implanted MNCs approximately 2 h after BM or PB aspiration by direct intramuscular injection into the gastrocnemius of the ischemic legs (4.0× 10 6 to 7.0×10 7 cells) and in the remaining patient, we implanted BM-MNCs not only into the gastrocnemius but also into the quadriceps femoris of the ischemic leg, because blood perfusion was significantly reduced at knee level. We implanted approximately 0.75 ml of BM-MNC or PB-MNC suspension into each injection site using a 26-gauge injection needle at 2.5×2.5 cm grid intersect as injection site markers.
Assessment of Limb Ischemia
Safety and efficacy of the treatment, defined as rest pain scale (visual analog scale: VAS), ankle -brachial blood pressure index (ABI) and transcutaneous oxygen pressure (TcO2) were reconfirmed. We measured ABI and TcO2 before, 1 day and 1, 2, 4 and 24 weeks after the TACT therapy. We used the criteria of Rutherford et al to assess limb status. 14 To measure ABI, we established Doppler-derived arterial segmental pressures on the ankle and brachium with a standard adult cuff, and indexed ankle systolic blood pressure against brachial systolic blood pressure (normal range >1.0). We judged an increase in ABI of more than 0.1 as an improvement, according to the standard assessment of interventional therapy for peripheral artery disease. 14 We measured TcO2 using an oxygen monitor (TCM4, Radiometer, Copenhagen, Denmark). After cleansing the measurement site with ethanol, we applied the probe, and heated the skin surface to 43.5°C. When a steady-state temperature was achieved, a value expressed in mmHg was recorded (normal range >60 mmHg). These measurements were performed while patients were supine. TcO2 was measured repeatedly, and the first measurement was performed when patients were breathing room air, and the second when they were given oxygen (6 L/min) for 5 min. We also assessed subjective symptoms by rest pain scale score [VAS; rated as 11 grades from 0 (pain free) to 10 (maximum pain)] before, 1 day and 1, 2, 4 and 24 weeks after the TACT therapy. Before and 4 weeks after the treatment we performed angiography in which the absolute amount of contrast medium, speed of contrast injection, and the position of the catheter tip were strictly fixed. Angiography and thermography were performed before and 4 weeks after the TACT therapy. Angiographically, we assessed new collateral vessel formation as 0 (no collateral development), +1 (slight), +2 (moderate), or +3 (rich). New collateral vessel formation was assessed by 2 interventional radiologists who were unaware of the treatment regimen.
Progenitor Cell Assay
Fluorescence-activated cell sorting (FACS) analysis revealed that circulating EPC expressed cell surface antigens such as CD34, CD133 and VEGF receptor 2 (VEGFR2). 15 We also counted those numbers in PB at 1 day, 3 days and 1, 2 and 4 weeks after the treatment according to the following equation: the numbers of (CD34 + , CD133 + and CD34 + CD133 + ) cells = white blood cell count × percentage of (CD34 + , CD133 + and CD34 + CD133 + ) cells measured by FACS analysis.
Statistical Analysis
All statistical analyses were conducted using StatView for Windows version 5.0 (SAS Institute Inc, Cary, NC, USA). All data are expressed as mean ± SEM. Significant differences between responders and non-responders were assessed by unpaired t-test. The value of p<0.05 was considered statistically significant. The number of circulating CD34 + and CD133 + cells was each translated into a logarithm, and the changes in the numbers of circulating CD34 + and CD133 + cells were compared between responders and non-responders by repeated measure ANOVA. The value of p<0.05 was considered statistically significant.
Results and Discussion
In this preliminary report, we treated 7 patients with CLI with cell transplantation according to the TACT protocol. 7 The clinical profiles of the 7 patients are shown in Table 1 : 3 patients had Buerger's disease and the other 4 had arteriosclerosis obliterans undergoing chronic hemodialysis (ASO-HD) (1 diabetic, 3 non-diabetic patients). All patients were treated safely. Among the 4 ASO-HD patients, 2 had a previous history of amputation. The observation period ranged from 5 to 39 months (mean 23.7 months).
Six patients received autologous BM-MNC transplantation (Table 2) , and the remaining patient (case 3) received PB-MNCs under intravenous anesthesia because a high risk was expected with general anesthesia. In 1 patient (case 7), we transplanted BM-MNCs not only into the gastrocnemius but also into the quadriceps femoris of the ischemic leg because blood perfusion was significantly reduced even above the knee.
In the early phase until 4 weeks after treatment, subjective symptoms assessed by VAS were improved in the 3 Buerger's disease patients and 2 of the ASO-HD patients (Fig 1) . Objective findings did not necessarily parallel the improvement on the VAS (Table 3) . Among the 5 patients with VAS improvement, the objective findings were improved in 3 (Fig 2, Table 3 ). In the present study, we defined responders as those who elicited improvements in both subjective symptoms and objective findings. Thus, 3 of 7 patients were overall responders.
In the acute phase, all 3 responders had Buerger's disease and all 4 non-responders had ASO-HD. In the chronic phase, of the 3 acute phase responders, 1 (case 1) had complete healing of an ischemic ulcer and maintained the improved status, 1 (case 5) relapsed with rest pain 6 months after cell transplantation, and 1 (case 7) underwent below-knee amputation at postoperative day 16, although above-knee amputation had been thought to be inevitable (Table 4) because preoperative angiography had shown almost avascularity at thigh level. Therefore, BM-MNCs were injected into not only the gastrocnemius, but also the quadriceps femoris, and the TcO2 below knee level had increased 2 weeks after cell transplantation (from 45 to 59 mmHg), and ultimately above knee amputation was avoided. For amputees salvage of the distal joints is important for quality of life, so we judged cell transplantation to be effective in this case. Thus, TACT seems to be safe and effective for patients with Buerger's disease.
Among the 4 non-responders (all ASO-HD patients), 3 underwent toes or below-knee amputation and 1 (case 3) died suddenly 5 months after cell transplantation (Table 4) . Considering the subject had high risk factors for systemic arteriosclerosis (past history including diabetic nephropathy, hemodialysis, coronary artery bypass graft, bypass graft and percutaneous transluminal angioplasty for ASO and previous amputation) and the situation at death, despite the lack of autopsy we consider that the cause of death was a cardiovascular event, such as ventricular tachyarrhythmia, acute myocardial infarction or stroke. This case of sudden death had little relation to the cell transplantation, because the TACT had no effect on therapeutic angiogenesis and seemed not to have any adverse effects on atherosclerosis progression or plaque. Therefore, TACT was less effective for end-stage ASO patients undergoing chronic hemodialysis. In a previous study, some ASO patients responded well to TACT, 7 and there are several reasons why the TACT protocol was not so effective in the present patients with ASO-HD. First, their limb status was very poor; for example, there were 2 cases of previous limb amputation. Second, all ASO-HD patients were on relatively long-term hemodialysis (13, 15, 17 and 19 years, respectively). It is well known that patients on chronic hemodialysis have reduced endothelial function, 16 reduced endothelium-derived nitric oxide (EDNO) release, 17 have severe atherosclerotic lesions systemically, 18 and thus have impaired angiogenic capability. We previously showed that EDNO is important for ischemia-induced angiogenesis, 19 and this process might be severely impaired in patients with ASO-HD. Additionally, a recent study showed that number and/or function of circulating EPC is markedly reduced in patients with various coronary risk factors, 10, 11 ischemic heart disease 20 and chronic kidney disease (CKD). 12 
Progenitor Cells in BM and Circulating Progenitor Cells
BM-derived EPCs can be incorporated into neovascularization, a process known as vasculogenesis. 2, 21 Therefore, it can be expected that the transplantation of a larger number of BM-MNC or progenitor cells would be more efficacious. Although the numbers of transplanted MNCs, CD34 + , CD133 + and CD34 + CD133 + cells were not significantly different between responders and non-responders in the present study, they tended to be greater in responders than non-responders ( Table 2 , Fig 3) . Among subjects with BM-MNC transplantation, the number of transplanted MNCs tended to be larger in responders than in non-responders (5.687±1.668 vs 1.867±0.481, p=0.09). However, the differences in the number of transplanted CD34 + , CD133 + and CD34 + CD133 + cells between the 2 groups was not so great ( (Fig 4) . Therefore, the postprocedural increase in circulating progenitor cell levels may indicate more powerful mobilization of progenitor cells from the BM in responders than in non-responders. Several mechanisms account for the relation between the increase in EPC level and clinical course. First, transplanted BM-MNCs secrete various angiogenic cytokines, such as VEGF, basic fibroblast growth factor (Fig 5) and angiopoietin-1, at the injection sites. 7, 22, 23 BM-MNC transplantation might cause further postprocedural mobilization of progenitor cells via secretion of these cytokines. Second, the number of circulating EPC is reduced in patients with risk factors for atherosclerosis, such as HT, DM, smoking, aging, and in patients with CKD. [10] [11] [12] [13] 24 Transplantation of BM physically helps progenitor cells mobilize in ischemic tissue. In this study, all non-responders had ASO-HD but because the sample size was only 3, the efficacy and feasibility of the present TACT protocol for ASO-HD subjects must be re-evaluated in a larger sample.
Passuer et al reported that patients on long-term hemodialysis showed reduced numbers of circulating CD34 + and CD34 + CD133 + cells, impaired migratory activity and EPC adhesion compared with control subjects, although the blood VEGF level was significantly elevated in the dialysis patients. 25 Taken together, augmentation of EPC mobilization from the BM might be impaired in patients with ASO-HD, probably because of reduced BM function.
Study Limitations
First, because the number of patients in this study is very small, larger scale clinical trials are needed. Second, mechanisms for the unresponsiveness of ASO-HD cases to this protocol need to be further clarified (eg, involvement of uremic toxin, impaired production of erythropoietin, etc). In addition, the mechanisms of the differential time course of the number of circulating EPCs according to responsiveness and the type of underlying disease (eg, Buerger's disease or ASO-HD) should be further investigated. We could not determine whether that the different time course of the progenitor cell levels in the subjects reflects responsiveness or disease condition or both.
Conclusions
TACT was performed safely, and the procedure per se was feasible in patients with CLI. Favorable efficacy occurred for patients with Buerger's disease but not in those with ASO-HD. The responders showed a continuous increase in the number of circulating progenitor cells after TACT and this unique feature may be related to the clinical efficacy of the procedure. The safety and efficacy of autologous progenitor cell transplantation were again reconfirmed in this study.
